# ReLIA Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/relia-biotech

- Industry: Medical Devices & Equipment
- Headquarters: Shenzhen, China
- Website: www.reliachina.com
- Latest round: Series C (May 1, 2018)
- Investors on record: 2

## About

Established in 2001 and based in Shenzhen, China, RELIA Biological Engineering (Shenzhen) Co., Ltd. is a medical company that provides rapid diagnostic service and two rapid detection systems, including multi-functional immunoassay system and immunofluorescence detection system. The company has a foundational R&D center in Silicon Valley, California, USA and R&D centers and production bases in Shenzhen and Taizhou. With a team exceeding 200 members and a R&D team of over 50 professionals, RELIA's leadership includes founder Dr. Willian J Rutter, a renowned entrepreneur in precision medicine with experience at Novartis and Abbott. The company also holds over 20 patents and more than 50 product certifications.

The company offers a range of bedside rapid testing systems, including a multifunctional immunoassay system and an immunofluorescence rapid testing system. Their testing projects cover rapid detection series for cardiovascular diseases, acute kidney injury, and rapid detection of inflammation and infectious diseases.

The company generates revenue by providing POCT devices and testing reagents.

## Funding rounds

- Series C, May 1, 2018 — Sinolink Securities, Gopher Asset Management

## Investors

- Sinolink Securities — Series C
- Gopher Asset Management (https://capitalatlas.ai/funds/gopher-asset-management) — Series C